Niagen Bioscience reports 30% sales growth in 2025
Niagen Bioscience reported 30% year‑over‑year net sales growth to $129.4 million for fiscal 2025, with net income rising 103% to $17.4 million and basic EPS of $0.22. Gross margin improved 250 basis points to 64.3%, adjusted EBITDA climbed 139% to $20.4 million, and cash and cash equivalents increased to $64.8 million. The company credited higher Tru Niagen product and ingredient sales, e-commerce growth and expanded market penetration while investing more in selling and marketing, R&D and clinical activities.
Why it mattersAdjusted EBITDA rose 139% to $20.4 million, increasing funds for clinical and marketing investment.
Entities Mentioned
Niagen Bioscience